POMATI, GIULIA
 Distribuzione geografica
Continente #
NA - Nord America 1.503
AS - Asia 1.101
EU - Europa 1.034
SA - Sud America 116
AF - Africa 87
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 1
Totale 3.846
Nazione #
US - Stati Uniti d'America 1.462
IT - Italia 594
SG - Singapore 338
CN - Cina 177
VN - Vietnam 169
HK - Hong Kong 159
DE - Germania 91
IN - India 91
BR - Brasile 85
SE - Svezia 83
FR - Francia 41
GB - Regno Unito 38
FI - Finlandia 35
CA - Canada 29
RU - Federazione Russa 28
JP - Giappone 24
NL - Olanda 23
ID - Indonesia 22
MA - Marocco 21
RO - Romania 21
BD - Bangladesh 18
PK - Pakistan 14
CI - Costa d'Avorio 13
IQ - Iraq 13
IR - Iran 13
ZA - Sudafrica 13
BG - Bulgaria 12
EG - Egitto 12
AT - Austria 11
TR - Turchia 11
IE - Irlanda 10
PH - Filippine 9
EC - Ecuador 8
KR - Corea 8
AR - Argentina 7
PL - Polonia 7
UA - Ucraina 7
ES - Italia 6
UZ - Uzbekistan 6
CO - Colombia 5
KE - Kenya 5
TG - Togo 5
TN - Tunisia 5
AU - Australia 4
CH - Svizzera 4
CZ - Repubblica Ceca 4
DZ - Algeria 4
LT - Lituania 4
MX - Messico 4
TH - Thailandia 4
TW - Taiwan 4
AZ - Azerbaigian 3
BO - Bolivia 3
DK - Danimarca 3
MK - Macedonia 3
SA - Arabia Saudita 3
SN - Senegal 3
AE - Emirati Arabi Uniti 2
AO - Angola 2
CL - Cile 2
CR - Costa Rica 2
EE - Estonia 2
GR - Grecia 2
IL - Israele 2
JM - Giamaica 2
JO - Giordania 2
KZ - Kazakistan 2
MY - Malesia 2
NI - Nicaragua 2
NP - Nepal 2
PY - Paraguay 2
VE - Venezuela 2
AL - Albania 1
BE - Belgio 1
CM - Camerun 1
ET - Etiopia 1
EU - Europa 1
GA - Gabon 1
GT - Guatemala 1
LB - Libano 1
PE - Perù 1
PS - Palestinian Territory 1
PT - Portogallo 1
RS - Serbia 1
SC - Seychelles 1
SK - Slovacchia (Repubblica Slovacca) 1
SY - Repubblica araba siriana 1
TT - Trinidad e Tobago 1
UY - Uruguay 1
Totale 3.846
Città #
Rome 253
Ashburn 223
Singapore 182
Hong Kong 155
San Jose 146
Dallas 115
Fairfield 90
Chandler 59
Ho Chi Minh City 57
Los Angeles 56
Houston 43
Hanoi 40
New York 39
Santa Clara 36
Seattle 34
Beijing 32
Munich 32
Hillsboro 31
Milan 30
Woodbridge 30
The Dalles 27
Lauterbourg 24
Cambridge 23
San Paolo di Civitate 23
Wilmington 23
Dearborn 20
Frankfurt am Main 20
Helsinki 20
Jakarta 19
Redondo Beach 19
Council Bluffs 18
Tokyo 18
Princeton 17
Bremen 15
Cosenza 15
Buffalo 14
Casablanca 14
Lawrence 13
Toronto 13
Abidjan 12
Sofia 11
Ann Arbor 10
Hefei 10
San Diego 10
Dublin 9
Guangzhou 9
Horia 9
London 9
Nuremberg 9
Boardman 8
Boston 8
Chicago 8
Johannesburg 8
Lappeenranta 8
Millbury 8
Portici 8
Vienna 8
Haiphong 7
Hyderabad 7
Mumbai 7
Phoenix 7
São Paulo 7
Turku 7
Baghdad 6
Bengaluru 6
Chennai 6
Clementon 6
Fremont 6
Tashkent 6
Amsterdam 5
Bologna 5
Columbus 5
Lahore 5
Lomé 5
Moscow 5
Nairobi 5
Orem 5
Redwood City 5
Atlanta 4
Brooklyn 4
Cagliari 4
Can Tho 4
City of London 4
Denver 4
Dhaka 4
Gujranwala 4
Hai Bà Trưng 4
Montreal 4
Naples 4
Ottawa 4
Plano 4
Poplar 4
Shanghai 4
Stockholm 4
Tanta 4
Turin 4
Ankara 3
Cairo 3
Cardiff 3
Charlotte 3
Totale 2.407
Nome #
Management of salivary gland malignant tumor: the Policlinico Umberto I, "Sapienza" University of Rome Head and Neck Unit clinical recommendations 221
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: a real-world experience 189
The role of opioids in cancer response to immunotherapy 186
Molecular profiling of male breast cancer by multigene panel testing: Implications for precision oncology 184
Exploratory pilot study of circulating biomarkers in metastatic renal cell carcinoma 181
Burned-out testicular cancer: really a different history? 178
PD-L1 testing in metastatic triple negative breast cancer: Results of an Italian survey 175
Immune-related toxicity and soluble profile in patients affected by solid tumors: a network approach 171
Weekly chemotherapy as first line treatment in frail head and neck cancer patients in the immunotherapy era 171
Prolactin as a potential negative predictive factor in metastatic non-small cell lung cancers (NSCLC) patients in treatment with Nivolumab (NIVO) 162
The role of soluble LAG3 and soluble immune checkpoints profile in advanced head and neck cancer: a pilot study 162
Induction chemotherapy in nonlaryngeal human papilloma virus-negative high-risk head and neck cancer: a real-world experience 160
Tryptophan Catabolism as Immune Mechanism of Primary Resistance to Anti-PD-1 152
The 5-Ws of immunotherapy in head and neck cancer 150
The impact of locoregional treatment on response to Nivolumab in advanced platinum refractory head and neck cancer: the NEED TRIAL 149
A network approach to define the predictive role of immune profile on tumor response and toxicity of anti PD-1 single agent immunotherapy in patients with solid tumors 140
The role of immune profile in predicting outcomes in cancer patients treated with immunotherapy 134
Standard of care and promising new agents for the treatment of mesenchymal triple-negative breast cancer 124
Comparative effects of Folfirinox and Gemcitabine/nab-paclitaxel as first and second line chemotherapy for metastatic pancreatic cancer: single choice or sequence 123
The predictive role of immune profile in patients with solid tumours in treatment with immunotherapy: a network analysis of efficacy and toxicity 120
The impact of drug–drug Interactions on the toxicity profile of combined treatment with BRAF and MEK Inhibitors in patients with BRAF-mutated metastatic melanoma 114
Primary squamous cell carcinoma of major salivary gland: “Sapienza Head and Neck Unit” clinical recommendations 114
PD-L1 testing in metastatic triple negative breast cancer: Results of an Italian survey 111
Network approach in liquidomics landscape 108
Network analysis to determine association between immuno-related toxicities and immune soluble profile in patients treated with anti-PD-1 102
Genomic and immune approach in platinum refractory HPV-negative head and neck squamous cell carcinoma patients treated with Immunotherapy: a novel combined profile 100
Antibiotics, the microbiome and gastrointestinal cancers: a causal interference? 89
The Oncotype DX® 21-gene recurrence score and clinical outcomes in hormone receptor-positive, HER2-negative male breast cancer: a scoping review 37
Totale 4.007
Categoria #
all - tutte 12.875
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.875


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202121 0 0 0 0 0 0 0 0 0 0 0 21
2021/2022254 41 15 12 12 28 14 6 17 14 7 63 25
2022/2023389 51 63 33 36 43 32 19 33 23 11 31 14
2023/2024404 24 38 38 30 47 60 62 36 10 27 17 15
2024/2025824 19 31 40 68 51 52 41 62 96 76 85 203
2025/20261.727 195 104 239 152 175 68 289 63 148 186 104 4
Totale 4.007